Amazon's Secret Autonomous Car!
Amazon (NASDAQ: AMZN) has been building a robotaxi business in secret for years, and the vehicle is finally ready for prime time. With a new factory up and running, Zoox may launch thousands of robotaxis in the coming years.
*Stock prices used were end-of-day prices of June 20, 2025. The video was published on June 24, 2025.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Should you invest $1,000 in Amazon right now?
Before you buy stock in Amazon, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $676,023!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,692!*
Now, it's worth noting Stock Advisor 's total average return is793% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Travis Hoium has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, Amazon, and Tesla. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
34 minutes ago
- The Market Online
AstraZeneca signals intent to join Inka Health's AI-driven oncology consortium
Onco-Innovations' (CBOE CA:ONCO) wholly-owned subsidiary, Inka Health Corp., has received a formal Expression of Interest (EOI) from AstraZeneca (NASDAQ:AZN) to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium The PROmAI Consortium, spearheaded by Inka Health, wants to advance AI methodologies to improve predictive modeling in oncology AstraZeneca's EOI could mark a significant step toward establishing a multi-stakeholder platform focused on enhancing the reliability, interpretability, and regulatory alignment of AI-driven insights in cancer research Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23 This content has been prepared in collaboration with Onco-Innovations Ltd . , a third-party issuer, and is intended for informational purposes only. Onco-Innovations' (CBOE CA:ONCO) wholly-owned subsidiary, Inka Health Corp., has received a formal Expression of Interest (EOI) from AstraZeneca (NASDAQ:AZN) to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium. The PROmAI Consortium, spearheaded by Inka Health, wants to advance AI methodologies to improve predictive modeling in oncology. The initiative seeks to address challenges in translational modeling, particularly during the transition from early- to late-stage clinical development, by integrating insights from pharmaceutical, data science, and clinical research sectors. AstraZeneca's EOI could mark a significant step toward establishing a multi-stakeholder platform focused on enhancing the reliability, interpretability, and regulatory alignment of AI-driven insights in cancer research. The company's involvement in the exploratory phase will include joint planning, early input into project direction, and strategic alignment on key use cases. Inka Health is still ready to mingle with other global pharmaceutical companies regarding participation in the Consortium and plans to provide further updates as these discussions progress. The PROmAI initiative will leverage a wide range of multimodal data—including molecular, clinical, and imaging datasets—combined with emerging techniques in causal AI. The goal is to foster innovation in predictive oncology, improve transparency in AI applications, and support frameworks that align with both regulatory and payer expectations. For Inka Health, the Consortium represents a strategic opportunity to lead the development of next-generation AI tools in oncology. The company's proprietary platform, SynoGraph, utilizes causal inference to identify patient subgroups most likely to respond to specific treatments, thereby supporting precision medicine and optimizing clinical trial design. Onco-Innovations views AstraZeneca's interest as a strong endorsement of the Consortium's potential to shape the future of oncology research and drug development. 'This is not just about proving that AI can work in oncology-it's about shaping how it should work in ways that matter to regulators, clinicians, and ultimately patients. Having AstraZeneca engage at this early stage signals a shared commitment to advancing practical, credible AI applications in one of medicine's most complex domains,' Paul Arora, CEO of Inka Health, said in a news release. 'As leaders in this space, we see PROmAI not only as a research initiative but as a foundation for setting standards around trust, utility, and translational impact in oncology-focused AI.' Onco-Innovations Ltd. studies cancer research and treatment, specializing in oncology. Onco-Innovations (CBOE CA:ONCO) closed 12.06 per cent higher on Friday at C$2.23. Join the discussion: Find out what everybody's saying about this stock on the Onco-Innovations Bullboard, and check out the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
Globe and Mail
37 minutes ago
- Globe and Mail
Public market insider selling at LQWD Technologies (LQWD)
Alex P. Guidi, a Director, disposed of 226,400 Common Shares on a direct ownership basis at a price of $8.746 on June 24th, 2025. This represents a $1,980,004 divestment of the company's shares and an account share holdings change of -13.4%. Let the insiders guide you to opportunity at
Globe and Mail
37 minutes ago
- Globe and Mail
My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy Now
I'm not getting any younger. These days, I'm thinking more and more about retiring and the stream of passive income that will allow me to thrive instead of merely surviving. I'm attracted to high yields like everybody else, but there are more important factors to consider. Ares Capital (NASDAQ: ARCC), W.P. Carey (NYSE: WPC), and Realty Income (NYSE: O) have been hovering at the top of my list of dividend stocks to buy because they do more than just offer a high yield. All three of these stocks have remarkable track records when it comes to maintaining and raising their payouts. At the moment, they offer yields that are more than triple the average yield you'd receive from the average dividend payer in the S&P 500 index. Put it together, and they're hard to ignore. 1. Ares Capital Ares Capital is the largest business development company (BDC) with shares that trade publicly. These specialized entities fill in the private lending gap created by American banks that no longer lend directly to midsize businesses. Starved for capital, midsize businesses are willing to borrow at very attractive interest rates. The weighted average yield on Ares Capital's $27 billion portfolio was 9.8% at the end of March. Ares Capital isn't shy about sharing its investment income with shareholders. Just about every penny earned is paid out to a quarterly dividend that offers an 8.7% yield at recent prices. The BDC has a tendency to make extra dividend payments in times of plenty rather than commit to a permanent payout increase. Investors seeking a reliable income base will be glad to know its quarterly payout has been rising, or at least stable, since 2009. Direct lending to midsize businesses can be risky, but Ares Capital's enormous footprint in the asset management space means it has plenty of excellent borrowers to choose from. The BDC is externally managed by a subsidiary of Ares Management, a leading global alternative investment manager with around $546 billion in assets under management. Members of Ares Capital's underwriting team have over 25 years of experience on average, and it shows. At the end of March, just 0.9% of Ares Capital's total investment portfolio was on nonaccrual status. 2. W.P. Carey If you're willing to accept a smaller yield upfront in exchange for frequent payout increases, consider W.P. Carey. Shares of this diversified real estate investment trust (REIT) have been under pressure since it spun off its office building portfolio in 2023 and lowered its dividend accordingly. Throughout the Great Recession, W.P. Carey managed to raise its quarterly payout. The COVID-19 pandemic pulled the rug out from under its office portfolio, but it only lowered its payout by 19.7% in 2023, plus shareholders received new shares of Net Lease Office Properties. W.P. Carey has raised its dividend every quarter since it spun off Net Lease Office Properties. At recent prices, it offers a huge 5.7% yield that investors can reasonably expect to grow significantly in the years ahead. Its portfolio is highly diversified. It's three largest tenants combined are responsible for just 7% of total rent payments received annually. In April, management told us to expect between $4.82 and $4.92 in adjusted funds from operations (FFO), a proxy for earnings used to evaluate REITs. That's more than enough to meet a dividend commitment currently set at an annualized $3.60 and raise it further. 3. Realty Income Like W.P. Carey, Realty Income is a diversified REIT with steadily growing profits produced by a large portfolio of commercial property. Its cash flows grow reliably because annual rent escalators are written into long-term net leases that transfer all the variable expenses associated with building ownership to the tenant. At recent prices, Realty Income shares offer a 5.7% yield and confidence that comes with a very long payout raising streak. The company recently raised its monthly dividend payout for the 131st time since going public in 1994. With a 56-year operating history and 15,627 commercial properties spread throughout eight countries, Realty Income can borrow at interest rates that its smaller peers can only dream about. The company recently sold around $1.5 billion worth of euro-denominated notes at an effective rate of just 3.7%. For many companies that own their facilities, selling their buildings to Realty Income and leasing them back is an increasingly popular financing option. With the vast majority of leaseable buildings still owned by the businesses that operate in them, investors can look forward to many more years of steady payout raises. Should you invest $1,000 in Ares Capital right now? Before you buy stock in Ares Capital, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ares Capital wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 23, 2025
